Nindhana Paranthaman
8 works · 209 citations · h-index 2
Top works
- Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
- Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.
- 797 Real-world treatment duration of atezolizumab+carboplatin+etoposide among older patients with extensive-stage small cell lung cancer (ES-SCLC) and the impact of performance status and brain metastases
- Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase 2 study.
- POSC11 Systematic Literature Review and Network Meta-Analysis of Immunotherapy, Targeted Agents, or Combination Regimens in Treatment-Naive Unresectable or Metastatic Melanoma
- A randomized, active-controlled phase 3 study of ivonescimab + FOLFOX versus bevacizumab + FOLFOX as first-line treatment of metastatic colorectal cancer (mCRC): HARMONi-GI3.
- 34414 Real-world treatment patterns of veterans with periocular basal cell carcinoma
- 43144 A Systematic Literature Review of Treatment Patterns and Outcomes Associated with Hedgehog Inhibitors in Periocular Basal Cell Carcinoma